Anitocabtagene autleucel — Competitive Intelligence Brief

Anitocabtagene autleucel (Anitocabtagene autleucel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR T-cell therapy. Area: Oncology.

phase 2 CAR T-cell therapy BCMA Oncology Biologic

Target snapshot

Anitocabtagene autleucel (Anitocabtagene autleucel) — Kite, A Gilead Company. Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anitocabtagene autleucel TARGET	Anitocabtagene autleucel	Kite, A Gilead Company	phase 2	CAR T-cell therapy	BCMA
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
ELRANATAMAB	ELRANATAMAB		marketed		BCMA, CD3	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Bcmaxcd3	TECLISTAMAB	Johnson & Johnson	marketed		CD3, BCMA	2022-01-01
Blenrep	BELANTAMAB MAFODOTIN	GSK	marketed		BCMA	2020-01-01
Teclistamab (Tec)	Teclistamab (Tec)	University of Heidelberg Medical Center	marketed	Bispecific T-cell engager (BiTE)	CD3 and BCMA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR T-cell therapy class)

1. Allife Medical Science and Technology Co., Ltd. · 1 drug in this class
2. Celgene · 1 drug in this class
3. ImmunityBio, Inc. · 1 drug in this class
4. Kite, A Gilead Company · 1 drug in this class